Cell Biophysics

, Volume 22, Issue 1–3, pp 147–164 | Cite as

Targeting of superantigens

  • Terje Kalland
  • Mikael Dohlsten
  • Lars Abrahmsén
  • Gunnar Hedlund
  • Per Björk
  • Peter A. Lando
  • Anette Sundstedt
  • Eva Åkerblom
  • Peter Lind


The bacterial superantigen staphylococcal enterotoxin A (SEA) is an extremely potent activator of T lymphocytes when presented on MHC class II antigens. In order to induce T lymphocytes to reject a tumor, we substituted the specificity of SEA for MHC class II molecules with specificity for tumor cells by combining SEA with a MAb recognizing colon carcinomas. Chemical conjugates or recombinant fusion proteins of the MAb C215 and SEA retained excellent antigen binding properties whereas the binding to MHC class II was markedly reduced. The hybrid proteins directed SEA responsive T cells to tumors with specificity determined by the specificity of the MAb. Significant tumor cell killing was obtained at picomolar concentrations of the hybrid proteins and was the result of direct cell mediated by cytotoxicity as well as production of tumoricidal cytokines by T cells. Targeting of superantigens represents a novel approach to specific immunomodulation and deserves further study as a potential therapy for malignant disease.

Index Entries:

Monoclonal antibodies SEA superantigen T lymphocyte colon cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Houghton, A.N. and Scheinberg, D.S. (1991). Monoclonal antibodies inComprehensive Textbook of Oncology (Moosa, A. K., Schimpff, C., and Robson, M. C., eds.), Williams and Wilkins, Baltimore, MD., p. 601.Google Scholar
  2. 2.
    Brown, S. L., Miller, R. A., and Levy, R. (1989). Anti-idiotype antibody therapy of B cell lymphoma.Sem. Oncol. 16, 199–210.Google Scholar
  3. 3.
    Denardo, G. L., Denardo, S. J., O’Grady, L. F., Hu, E., Systma, V. M., Mills, S. L., Levy, N. B., Macey, D. B., Miller, C. H., and Epstein, A. L. (1988) Treatment of B cell malignancies with131I LYM-1 monoclonal antibodies.Int. J. Cancer 3(Suppl.), 96–101.CrossRefGoogle Scholar
  4. 4.
    Harris, D. T. and Mastrangelo, M. J. (1989) Serotherapy of cancer.Sem. Oncol. 16, 180–198.Google Scholar
  5. 5.
    Jain, R. K. (1987) Transport of molecules in the tumor interstitium: a review.Cancer Res. 47, 3039–3051.PubMedGoogle Scholar
  6. 6.
    Gerlach, J. H. (1991) Development of drug and radiation resistance, inComprehensive Textbook of Oncology (Moosa, A. K., Schimpff, C., and Robson, M. C., eds.), Williams and Wilkins, Baltimore, MD, p. 143.Google Scholar
  7. 7.
    Fleischer, B. (1992) Superantigens.Curr. Opinion Immunol. 4, 392–395.CrossRefGoogle Scholar
  8. 8.
    Lafon, M., Lafage, M., Martinez-Arends, A., Ramirez, R., Vuillier, F., Charron, D., Lotteau, V., and Scott-Algara, D. (1992) Evidence for a viral superantigen in humans.Nature 358, 507–510.PubMedCrossRefGoogle Scholar
  9. 9.
    Marrack, P., and Kappler, J. (1990) The staphylococcal enterotoxins and their relatives.Science 248, 705–711.PubMedCrossRefGoogle Scholar
  10. 10.
    Fraser, J. D. (1989) High affinity binding sites of staphylococcal enterotoxins A and B to HLA-DR.Nature 339, 221–224.PubMedCrossRefGoogle Scholar
  11. 11.
    Fischer, H., Dohlsten, M., Lindvall, M., Sjögren, H. O., and Carlsson, R. (1989) Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines.J. Immunol. 142, 3151–3155.PubMedGoogle Scholar
  12. 12.
    Dellabona, P., Peccoud, J., Kappler, J., Marrack, P., and Mathis, D. (1990) Superantigens interact with MHC class II molecules outside of the antigen groove.Cell 62, 1115–1121.PubMedCrossRefGoogle Scholar
  13. 13.
    Fleischer, B., Gerardy-Schan, R., Metzroth, B., Carrel, S., Gerlach, D., and Köhler, W. (1991) An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction.J. Immunol. 146, 11–17.PubMedGoogle Scholar
  14. 14.
    Fleischer, B., and Schrezenmeier, H. (1988) Stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for MHC class II molecules on accessory target cells.J. Exp. Med. 167 1697–1708.PubMedCrossRefGoogle Scholar
  15. 15.
    Dohlsten, M., Lando, P. A., Hedlund, G., Trowsdale, J., and Kalland, T. (1990) Targeting of human cytotoxic T lymphocytes to MHC class II expressing cells by staphylococcal enterotoxins.Immunology 71, 96–100.PubMedGoogle Scholar
  16. 16.
    Lando, P. A., Hedlund, G., Dohlsten, M., and Kalland, T. (1991) Bacterial superantigens as anti-tumor agents: induction of tumor cytotoxicity in human lymphocytes by staphylococcal enterotoxin.Cancer Immunol. Immunother. 33, 231–237.PubMedCrossRefGoogle Scholar
  17. 17.
    Lando, P. A., Dohlsten, M., Kalland, T., Sjögren, H. O., and Carlsson, R. (1990) The TCR-CD3 complex is required for activation of human lymphocytes with staphylococcal enterotoxin A.Scand. J. Immunol. 31, 133–138.PubMedCrossRefGoogle Scholar
  18. 18.
    Kalland, T., Hedlund, G., Dohlsten, M., and lando, P. A. (1991) Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity.Curr. Topics Microbiol. Immunol. 174, 81–92.Google Scholar
  19. 19.
    Herrman, T., Maryanski, J. L., Romero, P., Fleischer, B., and MacDonald, H. R. (1990) Activation of MHC class I restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and Vß usage of the responder T cell.J. Immunol. 144, 1181–1186.Google Scholar
  20. 20.
    Hedlund, G., Dohlsten, M., Lando, P. A., and Kalland, T. (1990) Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells.Cell. Immunol. 129, 426–434.PubMedCrossRefGoogle Scholar
  21. 21.
    Lando, P. A., Dohlsten, M., Hedlund, G., Åkerblom, E., and Kalland, T. (1993) T cell killing of human colon carcinomas by monoclonal antibody-targeted superantigens.Cancer Immunol. Immunother. 36, 223–228.PubMedCrossRefGoogle Scholar
  22. 22.
    Hedlund, G., Dohlsten, M., Petersson, C., and Kalland, T. (1993) Superantigen based tumor therapy: in vivo activation of cytotoxic cells.Cancer Immunol. Immunother. 36, 89–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Newell, K. A., Ellenhorn, J. D. I., Bruce, D. S., and Bluestone, J. A. (1991) In vivo T-cell activation by-staphylococcal enterotoxin B prevents out-growth of a malignant tumor.Proc. Natl. Acad. Sci. USA 88, 1074–1078.PubMedCrossRefGoogle Scholar
  24. 24.
    Herman, A., Croteau, G., Sekaly, R. P., Kappler, J., and Marrack, P. (1990) HLA-DR alleles differ in their ability to present staphylococcal entero-toxins to T cells.J. Exp. Med. 172, 709–717.PubMedCrossRefGoogle Scholar
  25. 25.
    Larson, L. N., Johansson, C., Lindholm, L., and Holmgren, J. (1988) Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells.Int. J. Cancer 42, 877–882.PubMedGoogle Scholar
  26. 26.
    Dohlsten, M., Hedlund, G., Åkerblom, E., Lando, P. A., and Kalland, T. (1991) Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.Proc. Natl. Acad. Sci. USA 88, 9287–9281.PubMedCrossRefGoogle Scholar
  27. 27.
    Dohlsten, M., Hedlund, G., Segrén, S., Lando, P. A., Herrman, T., Kelly, A. P., and Kalland, T. (1991) Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor.Eur. J. Immunol. 21, 1229–1235.PubMedCrossRefGoogle Scholar
  28. 28.
    Björk, P., Jönsson, U., Svedberg, H., Larsson, K., Lind, P., Hedlund, G., Dohlsten, M., and Kalland, T. (1993) Isolation, partial characterization and molecular cloning of a human colon adenocarcinoma cell surface glycoprotein recognized by the C215 mouse monoclonal antibody.J. Biol. Chem., in press.Google Scholar
  29. 29.
    Ikejima, T., Dinarello, C. A., Gill, D. M., and Wolff, S. M. (1984) Induction of human interleukin-1 by a product of staphylococcus aureus associated with toxic shock syndrome.J. Clin. Invest. 73, 1312–1316.PubMedCrossRefGoogle Scholar
  30. 30.
    Johnson, H. M., Stanton, G. J., and Baron, S. (1977) Relative ability of mitogens to stimulate production of interferon by lymphoid cells and to induce suppression of the in vitro immune response.Proc. Soc. Exp. Biol. Med. 154, 49–56.Google Scholar
  31. 31.
    Carlsson, R. and Sjögren, H. O. (1985) Kinetics of IL-2 and interferon-ψ production, expression of IL-2 receptors, and cell proliferation in human mononuclear cells exposed to staphylococcal enterotoxin A.Cell. Immunol. 96, 175–182.PubMedCrossRefGoogle Scholar
  32. 32.
    Parsonnet, J. and Gillis, Z. A. (1988) Production of tumor necrosis factor by human monocytes in response to toxic shock syndrome toxin-1.J. Infect. Disease 158, 1026–1033.Google Scholar
  33. 33.
    Kemeney, N., Childs, B., Larchian, W., Rosado, K., and Kelsen, D. (1990). A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma.Cancer 66, 659–663.CrossRefGoogle Scholar
  34. 34.
    Lotze, M., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., and Rosenberg, S. A. (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer.Cancer 58, 2764–2769.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1993

Authors and Affiliations

  • Terje Kalland
    • 1
    • 2
  • Mikael Dohlsten
    • 1
    • 2
  • Lars Abrahmsén
    • 3
  • Gunnar Hedlund
    • 1
    • 2
  • Per Björk
    • 1
  • Peter A. Lando
    • 1
  • Anette Sundstedt
    • 1
  • Eva Åkerblom
    • 4
  • Peter Lind
    • 3
  1. 1.Kabi Pharmacia OncologyLundSweden
  2. 2.Department of Tumor ImmunologyLund UniversitySweden
  3. 3.Kabi Pharmacia Bioscience CenterStockholmSweden
  4. 4.Kabi Pharmacia TherapeuticsUppsalaSweden

Personalised recommendations